Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Tuesday, H.C. Wainwright analysts reiterated their Buy rating and $500 price target for Alnylam Pharmaceuticals stock (NASDAQ: NASDAQ:ALNY). This decision follows a recent fireside chat with the company’s management, including John Kennedy, Senior Vice President and Global Commercialization Lead for the TTR Franchise, and John Vest, Senior Vice President of Clinical Research. The stock, currently trading near its 52-week high of $307.19, has delivered an impressive 103.45% return over the past year. According to InvestingPro data, analysts maintain a consensus Buy recommendation, with price targets ranging from $212 to $500.
The analysts noted that the launch of AMVUTTRA (vutrisiran) for treating ATTR amyloidosis with cardiomyopathy is showing promising initial results. They anticipate a pivotal readout from the Phase 2 KARDIA-3 study of zilebesiran in the second half of 2025. Additionally, a Phase 3 trial for nucresiran, a next-generation TTR silencer, is expected to commence by year-end. InvestingPro analysis reveals 10+ additional insights about Alnylam’s potential, available in the comprehensive Pro Research Report.
Alnylam’s TTR business is reportedly tracking ahead of plan, driven by strong formulary access and utilization in both new and existing patients. The company is also expanding its site-of-care network, which is expected to enhance the uptake of its treatments. Analysts believe that innovation in dosing convenience and geographic expansion will further support long-term growth.
The company’s broader pipeline continues to advance with late-stage programs targeting central nervous system disorders, cardiometabolic diseases, and bleeding disorders. With multiple pivotal programs set to read out or begin within the next 12 months, analysts express confidence in Alnylam’s capacity to achieve sustained revenue growth.
In other recent news, Alnylam Pharmaceuticals has been the focus of several analyst reports and corporate developments. RBC Capital Markets reiterated an Outperform rating with a price target of $330, citing positive insights from engagements with Alnylam’s executives and the strong initial uptake of their product Amvuttra. Similarly, JPMorgan maintained an Overweight rating and increased their price target to $330, reflecting a positive outlook on Alnylam’s financial health and market performance based on recent sales data and product momentum. Stifel also maintained a Buy rating with a $345 target, optimistic about Amvuttra’s potential in treating cardiomyopathy and the company’s strategic positioning in the market.
Additionally, Alnylam shareholders approved several key governance measures at the 2025 Annual Meeting of Stockholders, including the Second Amended and Restated 2018 Stock Incentive Plan and the re-election of four directors. The company reported that the initial uptake of Amvuttra has exceeded expectations, with significant inclusion in institutional formularies. Analysts have noted that Alnylam could potentially dominate the market for transthyretin-mediated cardiomyopathy treatments, with expectations of commanding a substantial market share in the coming years. These developments indicate a period of strategic growth and positive reception from both analysts and stockholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.